Frontiers in Pharmacology (Sep 2022)

Interleukin 22 and its association with neurodegenerative disease activity

  • Wenjian Chen,
  • Jianpeng Wang,
  • Huaizhi Yang,
  • Yuankai Sun,
  • Bangjie Chen,
  • Yuchen Liu,
  • Yanxun Han,
  • Ming Shan,
  • Junfeng Zhan

Journal volume & issue
Vol. 13


Read online

It is worth noting that neuroinflammation is well recognized as a symptom of neurodegenerative diseases (NDs). The regulation of neuroinflammation becomes an attractive focus for innovative ND treatment technologies. There is evidence that IL-22 is associated with the development and progression of a wide assortment of NDs. For example, IL-22 can activate glial cells, causing them to generate pro-inflammatory cytokines and encourage lymphocyte infiltration in the brain. IL-22 mRNA is highly expressed in Alzheimer’s disease (AD) patients, and a high expression of IL-22 has also been detected in the brains of patients with other NDs. We examine the role of IL-22 in the development and treatment of NDs in this review, and we believe that IL-22 has therapeutic potential in these diseases.